XML 19 R10.htm IDEA: XBRL DOCUMENT v3.23.2
REVENUE
 6 Months Ended
Jun. 30, 2023
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
Revenues are derived primarily from the sale of dental equipment and dental and healthcare consumable products. Revenues are measured as the amount of consideration the Company expects to receive in exchange for transferring goods or providing services.

Net sales disaggregated by product category for the three and six months ended June 30, 2023 and 2022 were as follows:
Three Months EndedSix Months Ended
(in millions)2023202220232022
Equipment & Instruments$180 $169 $332 $335 
CAD/CAM129 138 242 254 
Connected Technology Solutions$309 $307 $574 $589 
Essential Dental Solutions$377 $380 $763 $736 
Orthodontics$86 $76 $172 $144 
Implants & Prosthetics184 188 357 381 
Orthodontic and Implant Solutions$270 $264 $529 $525 
Wellspect Healthcare$72 $72 $140 $142 
Total net sales$1,028 $1,023 $2,006 $1,992 

Net sales disaggregated by geographic region for the three and six months ended June 30, 2023 and 2022 were as follows:
Three Months EndedSix Months Ended
(in millions)2023202220232022
United States$362 $358 $713 $666 
Europe403 414 799 825 
Rest of World263 251 494 501 
Total net sales$1,028 $1,023 $2,006 $1,992 

Contract Assets and Liabilities

The Company does not typically have contract assets in the normal course of its business. Contract liabilities, which represent billings in excess of revenue recognized, are primarily related to advanced billings for customer aligner treatment where the performance obligation has not yet been fulfilled. The Company had deferred revenue of $111 million and $35 million recorded in Accrued liabilities and Other noncurrent liabilities, respectively, in the Consolidated Balance Sheets at June 30, 2023. The Company had deferred revenue of $91 million and $27 million recorded in Accrued liabilities and Other noncurrent liabilities, respectively, in the Consolidated Balance Sheets at December 31, 2022. The amount of deferred revenue as of December 31, 2022 which was disclosed in the Form 10-Q for the three months ended March 31, 2023 has been revised by $34 million to correct for an error in the amount previously disclosed. Although the Company determined that this error impacts the footnote disclosure only and does not materially impact the previously issued consolidated financial statements, this revision was made to provide comparability with current period disclosures. The Company recognized approximately $47 million of revenue during the current year which was previously deferred as of December 31, 2022. The Company expects to recognize a majority of the remaining deferred revenue within the next twelve months.
Allowance for Doubtful Accounts

Accounts and notes receivables-trade, net are stated net of allowances for doubtful accounts and trade discounts, which were $11 million at June 30, 2023 and $14 million at December 31, 2022. For the three and six months ended June 30, 2023 and 2022, changes to the provision for doubtful accounts including write-offs of accounts receivable that were previously reserved were insignificant. Changes to this provision are included in Selling, general, and administrative expenses in the Consolidated Statements of Operations.